IP Library Granted Patent US 8,088,625
Granted Patent B2
US 8,088,625 · App. 12/299,165 · Granted Jan 3, 2012

Method for detection of familial combined hyperlipidemia

Assignee: Denka Seiken Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,088,625
App. No.
12/299,165
Granted
Jan 3, 2012
Kind
B2
Abstract

An object of the present invention is to provide an excellent method for detection and diagnosis of familial combined hyperlipidemia. The present invention relates to a method for detection of familial combined hyperlipidemia by measuring the concentration of small, dense LDL cholesterol in a sample collected from a subject.

Claims (11)

1. A method for detection of familial combined hyperlipidemia, comprising, for a serum or plasma sample collected from a subject,

(i) separating small, dense low density lipoprotein (LDL) from other LDLs or eliminating cholesterols other than small, dense LDL, and then

(ii) measuring the concentration of small, dense LDL in the serum or plasma sample, wherein the subject having a small, dense LDL concentration of higher than a cutoff value of 40 mg/dL is diagnosed to have familial combined hyperlipidemia, and wherein the cutoff value is determined by producing a receiver operating characteristic (ROC) curve.

2. The method according to claim 1 , comprising measuring the concentration of small, dense LDL in the sample collected from the subject, in which sample the triglyceride or LDL-cholesterol level is normal.

3. The method according to claim 1 , wherein separation of small, dense LDL from other LDLs is achieved by performing reaction for LDL other than the small, dense LDL.

4. The method according to claim 1 , wherein said concentration of small, dense LDL higher than 40 mg/dL is used as the sole indicator of familial combined hyperlipidemia.

5. A method for determination of the risk of the occurrence of arteriosclerotic disease in a subject with familial combined hyperlipidemia, comprising for a serum or plasma sample collected from the subject:

(i) separating small, dense low density lipoprotein (LDL) from other LDLs or eliminating cholesterols other than small, dense LDL in the serum or plasma sample collected from the subject; and

(ii) measuring the concentration of small, dense LDL in the serum or plasma sample, wherein the subject having a small, dense LDL concentration of higher than a cutoff value of 40 mg/dL is determined to have the risk of the occurrence of arteriosclerotic disease, wherein the cutoff value is determined by producing a receiver operating characteristic (ROC) curve.

6. The method according to claim 5 , wherein separation of small, dense LDL from other LDLs is achieved by performing reaction for LDLs other than the small, dense LDL.

7. The method according to claim 5 , wherein said concentration of small, dense LDL higher than 40 mg/dL is used as the sole indicator of determination of the risk of the occurrence of arteriosclerotic disease.

Assignments (2)
MERGER Recorded Oct 5, 2020
From: DENKA SEIKEN CO., LTD.
To: DENKA COMPANY LIMITED
Reel/Frame 053976/0705 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2008
From: ITOH, YASUKI
To: DENKA SEIKEN CO., LTD.
Reel/Frame 021768/0779 →
Priority Claims (1)
JP 2006-127591 · May 1, 2006 · national
Continuity (1)
Related Publication 20090317846A1 · Dec 24, 2009